// App-Quantinova.ai

543 : Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Researchers

Presenter

  • John G. Gribben

Principal Investigators

  • Ryan Jacobs

  • Sebastian Grosicki

  • Krzysztof Giannopoulos

  • Tomasz Wrobel

  • Syed F. Zafar

  • Jennifer L. Cultrera

  • Suman Kambhampati

  • Alexey Danilov

  • John M. Burke

  • Jerome Goldschmidt

  • Douglas F. Beach

  • Scott F. Huntington

  • Javier Pinilla Ibarz

  • Jeff P Sharman

  • Tanya Siddiqi

  • Danielle M. Brander

  • John M. Pagel

  • Kathryn S. Kolibaba

  • Monika Dlugosz-Danecka

  • Nilanjan Ghosh

  • Peter Sportelli

  • Hari P. Miskin

  • Owen A. O'Connor

  • Michael S. Weiss

  • Ian W. Flinn

Medical Centers

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Department of Hematology, Lymphoma Division, Department of Hematology, Lymphoma Division, Assistant Professor of Medicine, Levine Cancer Institute/Atrium Health, Charlotte, NC

  • Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland

  • Medical University of Lublin, Lublin, Poland

  • Department of Hematology, Wroclaw Medical University, Wroclaw, Poland

  • Florida Cancer Specialists South / Sarah Cannon Research Institute, Ft Myers, FL

  • Florida Cancer Specialists South / Sarah Cannon Research Institute, Ft Myers, FL

  • Sarah Cannon Research Institute at Research Medical Center, Kansas City, MO

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • US Oncology Hematology Research Program, Rocky Mountain Cancer Centers,Aurora,Stati Uniti

  • Blue Ridge Cancer Centers / US Oncology Research, Blacksburg, VA

  • Pennsylvania Hospital, Philadelphia, PA

  • Yale Cancer Center, New Haven, CT

  • Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute,Seattle,Estados Unidos

  • Northwest Cancer Specialists, Yacolt, WA

  • Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC

  • TG Therapeutics, Inc., New York, NY

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United Kingdom

  • Poland

  • United States

Companies

  • TG Therapeutics, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Ublituximab

  • Umbralisib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02612311

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved